Hy-Line Brown chickens’ health is closely related to poultry productivity and it is mainly maintained by the immune system, healthy intestinal function, and microflora of chicken. Polysaccharides are biological macromolecules with a variety of activities that can be used as a potential prebiotic to improve poultry health. In this experiment, the function of Alhagi honey polysaccharides (AH) as an immunomodulator on the chicken was investigated. All chicken (120) were randomly distributed to four groups (five replicas/group, six hens/replica). A total of 0.5 mL water was taken orally by the chicken in control group. AH (0.5 mL) in different concentrations (three dosages, 0.3 g/kg, 0.6 g/k, and 1.2 g/kg) were used for the AH-0.3 g/kg, AH-0.6 g/k, and AH-1.2 g/kg group, respectively. The results showed that the growth performance of the chickens and the index of immune organs (the weight of immune organs/the body weight) were enhanced significantly after being AH-treated (p < 0.05). The content of sIgA and cytokines was upregulated remarkably in the intestine after being AH-treated (p < 0.05). The AH treatment significantly enhanced the intestinal epithelial barrier (p < 0.05). Moreover, the percentage of CD4⁺ and CD8⁺ T cells in the ileum, spleen, and serum were obviously upscaled (p < 0.05). In addition, the AH treatment significantly enhanced the production of short chain fatty acids (SCFAs) and improved the structure of gut microbiota (p < 0.05). In conclusion, we found that AH-1.2g/kg was the best dosage to improve the chicken’s health, and these data demonstrated that AH could be used as a potential tool to enhance growth performance through improving intestine function, immunity, and gut microbiome in chicken.

Although inactivated vaccines remain the primary strategy for preventing and controlling avian influenza virus, they fail to induce durable and systemic immune protection. Adjuvants are crucial for enhancing antigen immunogenicity and improving immune responses. In this study, we evaluated the adjuvant activity of naringenin (Nar) for H9N2 inactivated vaccine by detecting humoral immunity, cellular immunity, and viral challenge. The results demonstrated that Nar/H9N2 co-administration significantly increased IgG levels and hemagglutination inhibition (HI) titers. Nar/H9N2 promoted the formation of high-affinity antibodies by upregulating the expression of genes associated with B cell activation and germinal centers (GCs) formation, thus facilitating humoral immune responses. Concurrently, Nar/H9N2 vaccine enhanced T cell proliferation, CD4⁺and CD8⁺T cell differentiation, and the expression of Th1/Th2 cytokines, thereby promoting cellular immunity. Crucially, compared to the inactivated H9N2 vaccine alone, viral challenge experiments confirmed that Nar-adjuvanted immunization confers superior protection, markedly reducing viral shedding and minimizing damage to the trachea and lungs. These findings elucidate the capacity of naringenin to synchronize multifaceted immune activation through GCs optimization and T-cell modulation, establishing Nar as a viable candidate for poultry vaccine adjuvants.